ReAlta names David Marek CEO, Paolo Martini to lead R&D 

ReAlta Life Sciences Inc. named David Marek CEO and Paolo Martini chief R&D officer. Marek, who joined ReAlta’s board in January, was CEO of Myovant Sciences GmbH. Martini was CSO of Moderna Inc. (NASDAQ:MRNA). ReAlta is developing a pipeline of rare and acute inflammatory disease therapeutics.

Matthew Shaulis, chief commercial officer and U.S. president of Hansa Biopharma AB (SSE:HNSA), will step down in late September. The commercial team will report to President and CEO Søren Tulstrup while the company searches for a successor. ...